NasdaqCM - Nasdaq Real Time Price USD

Compugen Ltd. (CGEN)

Compare
1.7200 0.0000 (0.00%)
At close: October 11 at 4:00 PM EDT
1.7100 -0.01 (-0.58%)
After hours: October 11 at 6:46 PM EDT
Loading Chart for CGEN
DELL
  • Previous Close 1.7200
  • Open 1.7200
  • Bid 1.6700 x 100
  • Ask 1.7400 x 100
  • Day's Range 1.6950 - 1.7650
  • 52 Week Range 0.5300 - 3.0300
  • Volume 139,993
  • Avg. Volume 244,832
  • Market Cap (intraday) 154.003M
  • Beta (5Y Monthly) 2.64
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1000
  • Earnings Date Nov 5, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 5.00

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with na?ve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

cgen.com

68

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CGEN

View More

Performance Overview: CGEN

Trailing total returns as of 10/11/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CGEN
13.13%
TA-125
11.22%

1-Year Return

CGEN
97.70%
TA-125
17.99%

3-Year Return

CGEN
73.17%
TA-125
12.15%

5-Year Return

CGEN
57.43%
TA-125
35.94%

Compare To: CGEN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CGEN

View More

Valuation Measures

Annual
As of 10/11/2024
  • Market Cap

    152.78M

  • Enterprise Value

    63.80M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.58

  • Price/Book (mrq)

    2.64

  • Enterprise Value/Revenue

    1.49

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -22.31%

  • Return on Assets (ttm)

    -3.04%

  • Return on Equity (ttm)

    -15.84%

  • Revenue (ttm)

    42.72M

  • Net Income Avi to Common (ttm)

    -9.53M

  • Diluted EPS (ttm)

    -0.1000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    92M

  • Total Debt/Equity (mrq)

    5.19%

  • Levered Free Cash Flow (ttm)

    8.37M

Research Analysis: CGEN

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 6.7M
Earnings -2.12M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

4.00
5.00 Average
1.7200 Current
7.00 High
 

Company Insights: CGEN

People Also Watch